Melqart Asset Management’s Apogee Therapeutics APGE Stock Holding History

Melqart Asset Management’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.6M	Buy	+117,249	New	+$10.6M	1.48%	20

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Melqart Asset Management's APGE Position: Q2 2026 in Review

Melqart Asset Management opened a new position in Apogee Therapeutics (APGE) in Q2 2026: 117,249 shares worth $15.6M. The stake represents 1.48% of the portfolio and ranks #20 among its holdings.

288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Melqart Asset Management held 117,249 shares of Apogee Therapeutics worth $15.6M as of Q2 2026.
Apogee Therapeutics was a new Melqart Asset Management position in Q2 2026.
Apogee Therapeutics made up 1.48% of Melqart Asset Management's portfolio in Q2 2026, its #20 holding.
288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Melqart Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.